Xenon Pharmaceuticals (XENE) Change in Accured Expenses (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Change in Accured Expenses data on file, last reported at -$1.8 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.8 million, up 52.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.5 million (down 23.27% YoY), and the FY2025 annual result was $5.5 million, down 35.4% from the prior year.
• Change in Accured Expenses fell to -$1.8 million in Q1 2026 per XENE's latest filing, from $2.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $9.2 million in Q2 2024 and troughed at -$5.8 million in Q1 2022.
• A 5-year average of $1.4 million and a median of $2.1 million in 2022 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 270.75% in 2024 and fell as far as 744.78% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $6.0 million in 2022, then slumped by 61.76% to $2.3 million in 2023, then surged by 270.75% to $8.5 million in 2024, then plunged by 72.42% to $2.4 million in 2025, then tumbled by 176.54% to -$1.8 million in 2026.
• Business Quant data shows XENE's Change in Accured Expenses at -$1.8 million in Q1 2026, $2.4 million in Q4 2025, and $6.1 million in Q3 2025.